2025.05.14 (수)

  • 맑음속초24.0℃
  • 맑음22.4℃
  • 맑음철원23.0℃
  • 맑음동두천24.7℃
  • 맑음파주23.2℃
  • 맑음대관령20.7℃
  • 맑음춘천22.6℃
  • 구름많음백령도16.2℃
  • 맑음북강릉26.7℃
  • 맑음강릉28.2℃
  • 맑음동해23.8℃
  • 맑음서울23.7℃
  • 맑음인천23.4℃
  • 맑음원주24.5℃
  • 맑음울릉도20.3℃
  • 맑음수원23.0℃
  • 맑음영월23.4℃
  • 맑음충주23.7℃
  • 맑음서산22.5℃
  • 맑음울진22.3℃
  • 맑음청주24.1℃
  • 맑음대전24.5℃
  • 맑음추풍령23.1℃
  • 맑음안동24.0℃
  • 맑음상주24.5℃
  • 맑음포항25.5℃
  • 맑음군산24.1℃
  • 맑음대구24.2℃
  • 맑음전주24.8℃
  • 맑음울산23.5℃
  • 맑음창원23.0℃
  • 구름조금광주24.9℃
  • 맑음부산18.1℃
  • 맑음통영19.1℃
  • 구름많음목포22.6℃
  • 구름조금여수20.2℃
  • 구름많음흑산도19.2℃
  • 구름많음완도23.6℃
  • 구름조금고창23.0℃
  • 구름조금순천21.1℃
  • 맑음홍성(예)24.0℃
  • 맑음23.7℃
  • 흐림제주21.2℃
  • 구름많음고산22.2℃
  • 구름조금성산20.8℃
  • 구름많음서귀포22.3℃
  • 맑음진주22.1℃
  • 맑음강화22.8℃
  • 맑음양평22.6℃
  • 맑음이천23.4℃
  • 맑음인제23.3℃
  • 맑음홍천23.8℃
  • 맑음태백24.0℃
  • 맑음정선군24.3℃
  • 맑음제천22.5℃
  • 맑음보은22.8℃
  • 맑음천안22.8℃
  • 맑음보령24.2℃
  • 맑음부여24.0℃
  • 맑음금산24.9℃
  • 맑음23.8℃
  • 맑음부안24.2℃
  • 맑음임실22.5℃
  • 맑음정읍24.8℃
  • 맑음남원23.3℃
  • 맑음장수23.0℃
  • 맑음고창군23.9℃
  • 구름많음영광군24.0℃
  • 맑음김해시24.3℃
  • 맑음순창군23.9℃
  • 맑음북창원24.5℃
  • 맑음양산시23.7℃
  • 구름많음보성군21.4℃
  • 구름많음강진군22.4℃
  • 구름많음장흥20.9℃
  • 구름많음해남22.2℃
  • 구름많음고흥22.2℃
  • 맑음의령군23.9℃
  • 맑음함양군22.6℃
  • 맑음광양시22.7℃
  • 구름많음진도군20.4℃
  • 맑음봉화23.8℃
  • 맑음영주22.5℃
  • 맑음문경23.6℃
  • 맑음청송군25.9℃
  • 맑음영덕26.4℃
  • 맑음의성24.8℃
  • 맑음구미24.7℃
  • 맑음영천25.0℃
  • 맑음경주시26.1℃
  • 맑음거창23.2℃
  • 맑음합천23.9℃
  • 맑음밀양24.2℃
  • 맑음산청22.2℃
  • 맑음거제22.2℃
  • 맑음남해22.4℃
  • 맑음22.7℃
기상청 제공
Shoppy 로고
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
  • 해당된 기사를 공유합니다

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

EC grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which demonstrated that over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose[1,2]
Generalized pustular psoriasis (GPP) differs significantly from plaque psoriasis in both its disease mechanism and severity[2,3,4]
The EMA’s decision builds on existing approvals in the USA and Japan[5]

The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.[1] Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.[2, 4-7]

“The symptoms of GPP are devastating and cause immense pain as well as hospitalization during a flare. Increased GPP awareness that leads to accurate and faster diagnosis is one important step to improving the quality of life for people living with GPP,” said Frida Dunger Johnsson, Executive Director, IFPA. “Now with a specifically developed treatment, people living with GPP can be offered a new lease of life by effectively managing the impact of GPP flares.”

“We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases which we are investigating in further clinical trials” commented Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “Today’s news marks the first of what we hope will be a number of new treatment options from our accelerated late-stage portfolio with the potential to transform the lives of people for generations to come.”

The EC’s conditional approval of spesolimab is based on results from the pivotal EFFISAYIL® 1 Phase II clinical trial.[2] In the 12-week trial, patients experiencing a GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a moderate or severe pustulation of the skin. After one week, 54% of patients treated with a single dose of spesolimab showed no visible pustules compared to placebo (6%).[2] Adverse events were reported in 66% of patients treated with spesolimab and 56% of those receiving placebo after one week.[2] Infections were reported by 17% and 6% of patients in the spesolimab and placebo groups respectively (at week one).2 Serious adverse events were reported in 6% of patients treated with spesolimab (at week one).[2]

People living with GPP often do not receive a correct or timely diagnosis and may have their symptoms identified as other forms of psoriasis. A Global Delphi Consensus Project classified GPP as phenotypically, genetically, immunologically and histopathologically distinct from psoriasis vulgaris / plaque psoriasis based on a systematic literature review.[3] The growing list of regulatory approvals for spesolimab for the treatment of GPP flares underlines that the Delphi panel’s vision of improved diagnosis and treatment for people with GPP is increasingly achievable.

For the full press release and link to ‘Notes to Editors’ please click here:

Press release https://bit.ly/3j0BFfQ

Additional information

www.boehringer-ingelheim.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005586/en/

언론연락처: Boehringer Ingelheim Corporate Communications Media + PR Laura Lessenich +49 (6132) 77-173436

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기